MacroGenics Reports Positive Interim Phase 2 LINNET Results
The company said single-agent lorigerlimab showed encouraging preliminary clinical activity in clear cell gynecologic cancer.
The company said single-agent lorigerlimab showed encouraging preliminary clinical activity in clear cell gynecologic cancer.